News

July 17, 2017July 17, 2017

Kyprolis-Dexamethasone Combo Allows Relapsed Myeloma Patients to Live Longer, Amgen Says

Kyprolis (carfilzomib), when given with dexamethasone, lets relapsed myeloma patients live an average 7.6 months longer than those treated with Velcade (bortezomib) with dexamethasone — information that Amgen, which makes Kyprolis, hopes to ... Read more

July 14, 2017July 14, 2017

Kyprolis Regimen Reduces Risk of Death in Relapsed Multiple Myeloma Patients, Studies Show

News

Adding the proteasome inhibitor Kyprolis (carfilzomib) to the standard regimen of Revlimid (lenalidomide) and dexamethasone reduced the risk of death in patients with relapsed multiple myeloma by 21%, according ... Read more

July 12, 2017

KD025 Shows Promise for Chronic Graft-Versus-Host Disease, a Common Complication of Stem Cell Transplants

News

Kadmon reports that the first patient group treated in a Phase 2 trial of its drug KD025 for chronic graft-versus-host disease after going through bone marrow or stem cell ... Read more

July 10, 2017

Multiple Myeloma Research Foundation Is Planning $15 Million Immunotherapy Initiative

News

The Multiple Myeloma Research Foundation will be pumping $15 million into a cancer immunotherapy initiative over the next three years. The effort will start with the foundation asking immuno-oncology experts, pharmaceutical industry ... Read more

July 7, 2017July 7, 2017

FDA Suspends Keytruda Combination Trials for Myeloma After Patient Deaths

multiple myeloma, News

The U.S. Food and Drug Administration (FDA) has ordered Merck to suspend two Phase 3 and part of a Phase 1 clinical trials in which Keytruda (pembrolizumab) is tested in combination ... Read more

July 5, 2017July 5, 2017

FDA Approves Lab Test to Help Detect Myeloma

News

The U.S. Food and Drug Administration (FDA) recently approved a lab test to aid in the detection and diagnosis of myeloma and a range of other blood cancers. The ... Read more

June 30, 2017

Bristol-Myers Squibb Issues Four-year Follow-up Findings for Empliciti Triple Combo Therapy

News

Treatment with Empliciti (elotuzumab) plus Revlimid (lenalidomide) and dexamethasone (ELd) in patients with relapsed/refractory multiple myeloma (RRMM) continued to show effectiveness in the Phase 3 ELOQUENT-2 trial (NCT01239797) after ... Read more

June 28, 2017June 28, 2017

Potential Use of Ninlaro as Maintenance Therapy in Multiple Myeloma Shown in Phase 1/2 Trials

News

Patients with newly diagnosed multiple myeloma benefit significantly from a combination of Ninlaro (ixazomib) plus Revlimid (lenalidomide) and dexamethasone, followed by Ninlaro maintenance therapy, according to long-term follow-up data ... Read more

June 26, 2017June 26, 2017

76-year-old Don Wright Has New Goal After Completing 100 Marathons with Myeloma

News

Doctors told Don Wright he had five years to live when he was diagnosed with multiple myeloma in 2003. Instead of resigning himself to this fate, Wright began running ... Read more

June 23, 2017

FDA Will Review Amgen’s Request to Expand Use of Xgeva for Multiple Myeloma

News

The U.S. Food and Drug Administration (FDA) has accepted a supplemental biologics license application (sBLA) seeking to expand the currently approved indication of Xgeva (denosumab) to include patients with ... Read more

Most Popular Myeloma Articles This Month